Hangzhou Alltest Biotech Co., Ltd. (688606.SS)
CNY 61.86
(1.51%)
CNY 61.86
(1.51%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 180.57 Million CNY | -84.76% |
| 2022 | 1.18 Billion CNY | 54.75% |
| 2021 | 765.68 Million CNY | 12.73% |
| 2020 | 679.22 Million CNY | 766.15% |
| 2019 | 78.41 Million CNY | 38.98% |
| 2018 | 56.42 Million CNY | 65.13% |
| 2017 | 34.16 Million CNY | 124.66% |
| 2016 | 15.2 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 73.64 Million CNY | -6.88% |
| 2024 Q1 | 44.78 Million CNY | -43.31% |
| 2024 Q2 | 79.09 Million CNY | 76.58% |
| 2023 Q3 | 30.38 Million CNY | -0.87% |
| 2023 FY | 180.57 Million CNY | -84.76% |
| 2023 Q4 | 79.01 Million CNY | 160.04% |
| 2023 Q2 | 30.64 Million CNY | -24.38% |
| 2023 Q1 | 40.53 Million CNY | 123.07% |
| 2022 FY | 1.18 Billion CNY | 54.75% |
| 2022 Q3 | 57.83 Million CNY | -77.18% |
| 2022 Q2 | 253.5 Million CNY | -75.84% |
| 2022 Q1 | 1.04 Billion CNY | 270.26% |
| 2022 Q4 | -175.71 Million CNY | -403.8% |
| 2021 Q1 | 150.27 Million CNY | -50.17% |
| 2021 Q4 | 283.37 Million CNY | 81.4% |
| 2021 Q3 | 156.21 Million CNY | -11.15% |
| 2021 Q2 | 175.82 Million CNY | 17.0% |
| 2021 FY | 765.68 Million CNY | 12.73% |
| 2020 Q4 | 301.57 Million CNY | 380.32% |
| 2020 Q3 | 62.78 Million CNY | -77.8% |
| 2020 Q2 | 282.79 Million CNY | 781.7% |
| 2020 Q1 | 32.07 Million CNY | 102.29% |
| 2020 FY | 679.22 Million CNY | 766.15% |
| 2019 Q4 | 15.85 Million CNY | 0.0% |
| 2019 FY | 78.41 Million CNY | 38.98% |
| 2018 FY | 56.42 Million CNY | 65.13% |
| 2017 FY | 34.16 Million CNY | 124.66% |
| 2016 FY | 15.2 Million CNY | 0.0% |